Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
तुलना करने के लिए मीट्रिक्स | MRKR | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधMRKRपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −1.9x | −3.6x | −0.6x | |
PEG अनुपात | 0.65 | −0.09 | 0.00 | |
क़ीमत/बुक | 1.5x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 5.7x | 21.6x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | 390.8% | 87.2% | 44.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 2.2% | 6.1% | अनलॉक करें |